Developer docs
API playgroundTry for free, no card

Search company profiles

Chemistry

Full company profile

uuid000024p

Namestring
Chemistry
Legal namestring
Chemistry Ventures Management LLC
Websiteurl
chemistry.vc
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Chemistry is a San Francisco-based early-stage venture capital firm founded in October 2024 by three managing partners: Kristina Shen (formerly General Partner at Andreessen Horowitz and Partner at Bessemer), Mark Goldberg (formerly Partner at Index Ventures and an early business hire at Dropbox), and Ethan Kurzweil (formerly Managing Partner at Bessemer for 16 years). The firm operates with a lean team of approximately 10 people spanning investment, operations, and marketing functions. It launched with a $350 million debut fund and invests in AI and B2B software startups from seed through Series B, with a stated thesis of backing founders who combine technical expertise with commercial instincts.

The portfolio spans AI agents and customer experience (Decagon at $4.5B valuation, Serval, Didero), healthcare technology (Assort Health at $1.2B unicorn, Yuzu Health, Fathom Therapeutics), developer tools and AI infrastructure (Datacurve, Nova Intelligence), creative AI (ComfyUI at $500M), and productivity (Granola at $125M Series C, Noon). In addition, the three managing partners' personal track records include early investments in Twilio, Plaid, Twitch, HashiCorp, Intercom, LaunchDarkly, and PagerDuty. Chemistry co-invests regularly with tier-one firms including Coatue, Menlo Ventures, General Catalyst, Craft Ventures, Sutter Hill, Accel, and First Round Capital.

Chemistry's revenue model follows the standard VC structure: approximately 2% annual management fees on its $350M fund (implying ~$7M of fee revenue) plus 20% carried interest on exits above an 8% hurdle. As of mid-2026, no portfolio exits are disclosed, so carried interest is unrealized despite unicorn-level marks at Assort Health and Decagon. The firm distributes capital through direct investments, often leading or co-leading rounds, and reaches founders via portfolio referrals, personal networks of the partners, and community initiatives such as the Elements speaker series and NeurIPS activations.

Short descriptiontext

Chemistry is a San Francisco-based early-stage venture capital firm founded in 2024 with a $350M debut fund. Founded by former partners from Bessemer, a16z, and Index, it leads Seed through Series B investments in AI and B2B software startups.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
early stage venture capital, seed series A investing, AI software investments, founder backed funding, startup equity financing
Industry3 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Early-Stage Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeManaged Services
Description

Chemistry generates returns through carried interest on successful portfolio company exits (IPOs, acquisitions) and management fees on funds under management. As a VC firm founded by former partners from Bessemer, a16z, and Index, they deploy capital from their $350M fund into early-stage companies with the expectation of significant returns through equity appreciation.

chemistry.vc
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Chemistry is an early-stage venture capital firm that invests Seed through Series B funding rounds in AI, B2B software, healthcare, and developer-tooling startups, deploying capital from a $350M debut fund. The firm provides portfolio companies with capital, board participation, strategic introductions, hiring support, and follow-on funding, while institutional limited partners receive exposure to early-stage AI and software deal flow led by a team with prior experience at Andreessen Horowitz, Bessemer, Index, and Dropbox. Revenue is generated through management fees on the fund and carried interest on successful exits.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Chemistry is a venture capital firm that provides early-stage investment services to founders, backing companies from initial investment through Series B stage. The firm focuses on technical expertise and commercial instincts, with investments spanning across AI/ML, healthcare technology, developer tools, creative AI, and enterprise software sectors. Their investment approach emphasizes being 'all in from day one' with portfolio companies.

Product and service3 records
1Chemistry Debut Early-Stage Venture Fund
CategoryVenture Capital Fund
Description

A $350M venture capital fund that invests from first check through Series B in AI, B2B software, healthcare, and developer-tooling startups; available to qualified institutional limited partners and family offices.

2Seed and Series A Lead Investment Program
CategoryStartup Equity Financing
Description

Lead or co-lead equity financing at Seed and Series A stages for early-stage AI and software founders, typically investing from first check through Series B with board participation, strategic introductions, hiring support, and follow-on funding.

3Elements Series (Content and Speaker Program)
CategoryContent and Community Program
Description

An ongoing editorial and event program featuring conversations with founders and operators—past guests include Brad Lightcap (OpenAI), Ashwin Sreenivas (Decagon), and Kristen Faulkner (Olympic athlete)—used by Chemistry for brand building and ecosystem engagement.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-10-01
Description

Forbes featured Chemistry prominently in October 2024 coverage titled 'Former Partners From Index, Bessemer, A16z Raise $350 Million For New VC Firm Chemistry', providing brand exposure and credibility for the new fund launch.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European-origin multi-stage venture firm where Mark Goldberg was previously a Partner. Strong franchise in early-stage software and fintech investing with comparable Seed/Series A activity and portfolio support model.

TypeDirect peer
Description

Seed-stage specialist with a strong founder community and operational support model similar to Chemistry's approach. Co-investor in Chemistry's Noon round and directly comparable in Seed/Series A focus.

TypeDirect peer
Description

Early-stage focused venture firm with SaaS and AI emphasis. Led ComfyUI's funding round with Chemistry participating and operates with comparable check sizes at Seed/Series A.

TypeBroad incumbent
Description

Large, founder-led venture firm with deep early-stage AI and biotech investing. Broader portfolio and larger fund sizes than Chemistry, but directly comparable in early-stage AI conviction and willingness to lead Seed/Series A.

TypeDirect peer
Description

Multi-stage venture firm with significant early-stage activity across enterprise software, healthcare, and fintech. Co-led Yuzu Health's Series A alongside Chemistry and represents a comparable stage-and-thesis peer.

TypeDirect peer
Description

Top-tier multi-stage venture firm and the prior employer of two Chemistry managing partners (Kristina Shen and Ethan Kurzweil). Invests across stages including Seed/Series A in software, with comparable AI and enterprise software focus.

TypeDirect peer
Description

Large multi-stage venture firm where Kristina Shen was previously a General Partner. Active at Seed/Series A in AI, B2B software, healthcare, and fintech with a comparable founder-friendly, thesis-driven approach.

TypeDirect peer
Description

Multi-stage venture firm with significant Seed/Series A activity in enterprise software, AI, and consumer. Comparable in fund size band and stage focus, with similar depth in B2B software investing.

TypeDirect peer
Description

Multi-stage venture firm with active early-stage practice in enterprise software and AI. Led Assort Health's unicorn Series C with Chemistry participating, demonstrating a comparable early-stage focus and stage-co-investment pattern.

TypeDirect peer
Description

Long-standing early-stage-focused venture firm known for leading Seed and Series A rounds in enterprise software and consumer. Directly comparable in stage specialization and AI/B2B software focus, and a co-investor in Chemistry's Nova Intelligence round.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment22 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chemistry

Early-Stage Venture Capitalchemistry.vc

Chemistry is a San Francisco-based early-stage venture capital firm founded in 2024 with a $350M debut fund. Founded by former partners from Bessemer, a16z, and Index, it leads Seed through Series B investments in AI and B2B software startups.

What Chemistry does

Chemistry is a San Francisco-based early-stage venture capital firm founded in October 2024 by three managing partners: Kristina Shen (formerly General Partner at Andreessen Horowitz and Partner at Bessemer), Mark Goldberg (formerly Partner at Index Ventures and an early business hire at Dropbox), and Ethan Kurzweil (formerly Managing Partner at Bessemer for 16 years). The firm operates with a lean team of approximately 10 people spanning investment, operations, and marketing functions. It launched with a $350 million debut fund and invests in AI and B2B software startups from seed through Series B, with a stated thesis of backing founders who combine technical expertise with commercial instincts.

The portfolio spans AI agents and customer experience (Decagon at $4.5B valuation, Serval, Didero), healthcare technology (Assort Health at $1.2B unicorn, Yuzu Health, Fathom Therapeutics), developer tools and AI infrastructure (Datacurve, Nova Intelligence), creative AI (ComfyUI at $500M), and productivity (Granola at $125M Series C, Noon). In addition, the three managing partners' personal track records include early investments in Twilio, Plaid, Twitch, HashiCorp, Intercom, LaunchDarkly, and PagerDuty. Chemistry co-invests regularly with tier-one firms including Coatue, Menlo Ventures, General Catalyst, Craft Ventures, Sutter Hill, Accel, and First Round Capital.

Chemistry's revenue model follows the standard VC structure: approximately 2% annual management fees on its $350M fund (implying ~$7M of fee revenue) plus 20% carried interest on exits above an 8% hurdle. As of mid-2026, no portfolio exits are disclosed, so carried interest is unrealized despite unicorn-level marks at Assort Health and Decagon. The firm distributes capital through direct investments, often leading or co-leading rounds, and reaches founders via portfolio referrals, personal networks of the partners, and community initiatives such as the Elements speaker series and NeurIPS activations.

Chemistry firmographics

Firmographics
Name
Chemistry
Legal name
Chemistry Ventures Management LLC
Website
https://chemistry.vc
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
101–250 employees
Short description
Chemistry is a San Francisco-based early-stage venture capital firm founded in 2024 with a $350M debut fund. Founded by former partners from Bessemer, a16z, and Index, it leads Seed through Series B investments in AI and B2B software startups.
Ownership category
akta.pro rank

Chemistry industry classification

Industry
Product category
Early-Stage Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)

Keywords

  • Early stage venture capital
  • Seed series A investing
  • AI software investments
  • Founder backed funding
  • Startup equity financing

Where Chemistry is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Chemistry business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Venture Capital Returns: Chemistry generates returns through carried interest on successful portfolio company exits (IPOs, acquisitions) and management fees on funds under management. As a VC firm founded by former partners from Bessemer, a16z, and Index, they deploy capital from their $350M fund into early-stage companies with the expectation of significant returns through equity appreciation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Chemistry product offering

Product offering

Core offering

Chemistry is an early-stage venture capital firm that invests Seed through Series B funding rounds in AI, B2B software, healthcare, and developer-tooling startups, deploying capital from a $350M debut fund. The firm provides portfolio companies with capital, board participation, strategic introductions, hiring support, and follow-on funding, while institutional limited partners receive exposure to early-stage AI and software deal flow led by a team with prior experience at Andreessen Horowitz, Bessemer, Index, and Dropbox. Revenue is generated through management fees on the fund and carried interest on successful exits.

Product overview

Chemistry is a venture capital firm that provides early-stage investment services to founders, backing companies from initial investment through Series B stage. The firm focuses on technical expertise and commercial instincts, with investments spanning across AI/ML, healthcare technology, developer tools, creative AI, and enterprise software sectors. Their investment approach emphasizes being 'all in from day one' with portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Chemistry Debut Early-Stage Venture Fund A $350M venture capital fund that invests from first check through Series B in AI, B2B software, healthcare, and developer-tooling startups; available to qualified institutional limited partners and family offices.
  • Seed and Series A Lead Investment Program Lead or co-lead equity financing at Seed and Series A stages for early-stage AI and software founders, typically investing from first check through Series B with board participation, strategic introductions, hiring support, and follow-on funding.
  • Elements Series (Content and Speaker Program) An ongoing editorial and event program featuring conversations with founders and operators—past guests include Brad Lightcap (OpenAI), Ashwin Sreenivas (Decagon), and Kristen Faulkner (Olympic athlete)—used by Chemistry for brand building and ecosystem engagement.

Companies that use Chemistry

Customer profile

Segments2 records

Ideal customer profiles2 records

Chemistry technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Chemistry partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ForbesminorGTM or Marketing Partner · 1 October 2024Forbes featured Chemistry prominently in October 2024 coverage titled 'Former Partners From Index, Bessemer, A16z Raise $350 Million For New VC Firm Chemistry', providing brand exposure and credibility for the new fund launch.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Chemistry competitors and assessment

Company assessment

Direct peers

  • Index Ventures: European-origin multi-stage venture firm where Mark Goldberg was previously a Partner. Strong franchise in early-stage software and fintech investing with comparable Seed/Series A activity and portfolio support model.
  • First Round Capital: Seed-stage specialist with a strong founder community and operational support model similar to Chemistry's approach. Co-investor in Chemistry's Noon round and directly comparable in Seed/Series A focus.
  • Craft Ventures: Early-stage focused venture firm with SaaS and AI emphasis. Led ComfyUI's funding round with Chemistry participating and operates with comparable check sizes at Seed/Series A.
  • General Catalyst: Multi-stage venture firm with significant early-stage activity across enterprise software, healthcare, and fintech. Co-led Yuzu Health's Series A alongside Chemistry and represents a comparable stage-and-thesis peer.
  • Bessemer Venture Partners: Top-tier multi-stage venture firm and the prior employer of two Chemistry managing partners (Kristina Shen and Ethan Kurzweil). Invests across stages including Seed/Series A in software, with comparable AI and enterprise software focus.
  • Andreessen Horowitz (a16z): Large multi-stage venture firm where Kristina Shen was previously a General Partner. Active at Seed/Series A in AI, B2B software, healthcare, and fintech with a comparable founder-friendly, thesis-driven approach.
  • Lightspeed Venture Partners: Multi-stage venture firm with significant Seed/Series A activity in enterprise software, AI, and consumer. Comparable in fund size band and stage focus, with similar depth in B2B software investing.
  • Menlo Ventures: Multi-stage venture firm with active early-stage practice in enterprise software and AI. Led Assort Health's unicorn Series C with Chemistry participating, demonstrating a comparable early-stage focus and stage-co-investment pattern.
  • Accel: Long-standing early-stage-focused venture firm known for leading Seed and Series A rounds in enterprise software and consumer. Directly comparable in stage specialization and AI/B2B software focus, and a co-investor in Chemistry's Nova Intelligence round.

Broad incumbents

  • Khosla Ventures: Large, founder-led venture firm with deep early-stage AI and biotech investing. Broader portfolio and larger fund sizes than Chemistry, but directly comparable in early-stage AI conviction and willingness to lead Seed/Series A.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Chemistry social profiles

Digital presence

Chemistry financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chemistry leadership team

Management profile

Number of profiles

Profiles9 records

Chemistry funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chemistry M&A and investment

M&A and investment

M&A

Investments22 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemistry

What does Chemistry do?

Chemistry is an early-stage venture capital firm that invests Seed through Series B funding rounds in AI, B2B software, healthcare, and developer-tooling startups, deploying capital from a $350M debut fund. The firm provides portfolio companies with capital, board participation, strategic introductions, hiring support, and follow-on funding, while institutional limited partners receive exposure to early-stage AI and software deal flow led by a team with prior experience at Andreessen Horowitz, Bessemer, Index, and Dropbox. Revenue is generated through management fees on the fund and carried interest on successful exits.

Is Chemistry a public or private company?

Chemistry is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Chemistry founded?

Chemistry was founded in 2024. It employs 101 to 250 people.

Where is Chemistry based?

Chemistry is headquartered in San Francisco, United States, in the North America region.

How does Chemistry make money?

One revenue line is on record: venture Capital Returns.

Who are Chemistry's main competitors?

Direct peers on record are Index Ventures, First Round Capital, Craft Ventures, General Catalyst, Bessemer Venture Partners, Andreessen Horowitz (a16z), Lightspeed Venture Partners, Menlo Ventures and Accel. Khosla Ventures is listed as a broad incumbent.

Does Chemistry have an API?

No public API is recorded for Chemistry.

What industry is Chemistry in?

Chemistry's product category is Early-Stage Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAA, Early-Stage Venture Capital (Pre-Seed/Seed). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Meticulous Raises $15 Million Series A Led By Chemistry To Expand Software Testing PlatformMeticulous raised $15 million in Series A funding led by Chemistry to expand its software testing platform. The company's autonomous testing system detects changes as small as a single-pixel difference across user flows. Customers include Notion, ElevenLabs, Dropbox, Wiz, and LaunchDarkly.FinSMEsMeticulou Raises $15M in Series A FundingMeticulous, a London-based automated software testing platform, raised $15M in Series A funding led by Chemistry with participation from Menlo Ventures and angel investors. The company will use the funds to expand operations and development. The platform generates and maintains thousands of flows to test code changes autonomously.FinSMEsProximal Raises USD15M in Funding at USD300M ValuationProximal, a New York City-based AI coding data startup, emerged from stealth with $15M in funding at a $300M valuation. The round was led by General Catalyst, with participation from SV Angel, Go Global Ventures, and Chemistry. The company will use the capital to expand engineering and research teams and accelerate expansion into new domain verticals.链捕手 ChainCatcherLiquid Compute completed a $15 million seed r...Liquid Compute completed a $15 million seed round and applied for CFTC Designated Contract Market and Derivatives Clearing Organization qualifications. The company aims to build a regulated order book for computing power contracts, with co-leaders Chemistry and FirstMark Cap. It has collaborated with financial institutions for OTC trading.Venture Capital Access OnlineLiquid Compute Launches with $15M to Build a Regulated Exchange for AI InfrastructureLiquid Compute emerged from stealth with $15 million in seed funding co-led by FirstMark and Chemistry. The company has pending CFTC applications for a regulated cash-settled exchange for AI infrastructure. It will use the funds to build matching and clearing infrastructure and expand compute availability.SuperbCrewWafer Raises $40M In Series A Funding RoundWafer, a San Francisco-based AI inference optimization company, closed a $40M Series A co-led by Marathon and Chemistry at a ~$200M valuation. The company reached $8M ARR with a team of under 10, and the proceeds will fund capacity expansion and hiring.Pulse 2.0Wafer Raises $40 Million Series A To Scale AI Inference Optimization PlatformWafer raised $40 million in Series A funding co-led by Marathon Management Partners and Chemistry. The company is developing an AI-powered platform to continuously optimize AI inference deployments, targeting cost reduction and performance improvement. The capital will accelerate development and support scaling the platform.FinSMEsWafer Raises $40M in Series A FundingWafer, a San Francisco-based AI inference chip startup, raised $40M in Series A funding led by Marathon and Chemistry. The company will use the capital to fund compute and wafer manufacturing, expand engineering, and accelerate customer onboarding. It develops high-performance inference chips and software infrastructure for generative AI.The SaaS NewsWafer Raises $40M Series AWafer, an AI inference optimization company, raised $40 million in a Series A round co-led by Marathon and Chemistry. The funds will automate its inference optimization loop and accelerate development of its infrastructure. The round also included participation from Wing, AMD Ventures, and other investors.WowtaleAI Inference Optimizer Wafer Raises $40 Million Series AWafer raised a $40 million Series A co-led by Marathon Management Partners and Chemistry, valuing the AI inference optimizer at over $200 million. The company's agents achieve 2-2.8x speedups and AMD's MI355X reached 80% of B200 throughput at half the cost. Capital will automate more of the inference optimization loop.